Reviews/Ssris and Snris/SSRIs and SNRIs reduce depressive symptoms versus placebo in MDD
· SS-MDD-01 · v2
The question is whether two common classes of antidepressants, SSRIs and SNRIs, work better than a dummy pill at easing depression. In this evidence set, a pooled analysis of eight double-blind trials [11] found both an SNRI (venlafaxine) and SSRIs reduced depression scores more than placebo, and a separate controlled trial [4] showed the same direction for both an SSRI and an SNRI, though in people whose depression accompanied Parkinson disease rather than depression on its own. The direction of benefit is consistent across both sources. The panel did not go higher because the support is thin: effectively one on-target pooled analysis plus one trial in a different patient group, the SSRI advantage over placebo in [11] was small, and the pooled dataset was tied to a drug manufacturer. Most of the other retrieved papers tested add-on or head-to-head designs that do not put either class against placebo at all. That combination supports a positive but not a settled conclusion.
A pooled analysis of eight randomized, double-blind controlled depression studies [11] reported mean HAM-D21 decreases of 14.5 for venlafaxine and 12.6 for SSRIs versus 11.3 for placebo, with the same pattern on MADRS (17.8 and 15.9 versus 12.9) and on response rates. A randomized, double-blind, placebo-controlled trial [4] found 12-week HAM-D reductions relative to placebo of 6.2 points for paroxetine (97.5% CI 2.2 to 10.3, p = 0.0007) and 4.2 points for venlafaxine XR (97.5% CI 0.1 to 8.4, p = 0.02), concluding both significantly improved depression, though in Parkinson disease. Both an SSRI and an SNRI beat placebo in each source, so the direction holds for both classes. The remaining primary-research papers test augmentation [2, 3, 7], active comparators [5, 6, 8] or switching [12] rather than either class against placebo. The contested point: The evidence divides on whether this thin base can carry a class-wide claim in general MDD: [11] is a single, manufacturer-associated pooled dataset and the SSRI-over-placebo gap it reports is only 1.3 HAM-D21 points (12.6 vs 11.3). The one corroborating placebo-controlled trial [4] is in Parkinson-disease depression, not primary MDD, leaving the magnitude and the direct-population support open to question.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Ssris and Snris, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim in MDD rests on a single on-target source [11]; one pooled analysis is not independent replication and cannot establish a class-wide effect on its own.
[11] is a manufacturer-associated pooled dataset of venlafaxine trials; selective trial inclusion or sponsorship bias could inflate the active-versus-placebo contrast.
Where it remains uncertain. The direct MDD support rests on one sponsored pooled analysis [11] with a small 1.3-point SSRI-versus-placebo increment, and the only corroborating placebo-controlled trial [4] is in Parkinson-disease depression rather than primary MDD.
Aleatory
The SSRI-over-placebo HAM-D21 gap in [11] is 1.3 points (12.6 vs 11.3), close to the placebo response and subject to between-patient variability that can swamp a small mean difference.
Epistemic
Only [11] tests the claim directly in depressed patients; a single pooled analysis is not independent replication, and more placebo-controlled MDD trials would reduce this.
Inferential
[4] is depression of Parkinson disease, not primary MDD; motor and neurological confounding and a distinct responder profile limit how far its placebo-controlled result transfers to the claim's population.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Placebo-controlled RCT showing both an SSRI and an SNRI significantly outperform placebo on HAM-D, in the indirect population of depression in Parkinson disease.
“Treatment effects (relative to placebo), expressed as mean 12-week reductions in HAM-D score, were 6.2 points (97.5% confidence interval [CI] 2.2 to 10.3, p = 0.0007) in the paroxetine group and 4.2 points (97.5% CI 0.1 to 8.4, p = 0.02) in the venlafaxine XR group.”
Panel auditInternal validity: high · scope of inference: Depression (including subsyndromal) in Parkinson disease, not MDD.Key limitations: population is PD depression not MDD · includes subsyndromal depression · small treatment arms
Direct primary-data evidence that both SSRIs and the SNRI venlafaxine reduce depressive symptoms significantly more than placebo in depressed patients.
“Statistically significant differences in mean HAM-D(21) score decrease between venlafaxine (14.5) and SSRIs (12.6) and between the active treatments and placebo (11.3) were observed.”
Panel auditInternal validity: medium · scope of inference: Depressed patients; SNRI and SSRI efficacy versus placebo.Key limitations: pooled not individual-patient data · possible sponsor framing · MDD diagnostic detail not given
2 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Two included sources consistently show both SSRIs and SNRIs beating placebo, but the thin and partly indirect corpus supports a Likely rather than an Established verdict.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent placebo-controlled MDD replication. The direct support rests on one sponsored pooled analysis [11]; the claim cannot be independently confirmed from this corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A pre-registered, independently funded, double-blind randomized trial of an SSRI and an SNRI versus placebo in primary MDD reporting HAM-D or MADRS change.
Open question: Is the SSRI and SNRI advantage over placebo in primary MDD reproducible outside a single manufacturer-associated pooled dataset? Why it is still open: The only direct on-target source [11] is one sponsored pooled analysis with no independent replication in the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19